Grifols, S.A. (NASDAQ:GRFS) Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC grew its holdings in Grifols, S.A. (NASDAQ:GRFS) by 44.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 4,959 shares of the biotechnology company’s stock after buying an additional 1,527 shares during the period. GAMMA Investing LLC’s holdings in Grifols were worth $37,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Signaturefd LLC increased its stake in Grifols by 66.2% in the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 2,153 shares during the period. AQR Capital Management LLC purchased a new stake in shares of Grifols in the second quarter valued at about $89,000. HighTower Advisors LLC boosted its holdings in shares of Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 1,546 shares in the last quarter. Tidal Investments LLC acquired a new position in shares of Grifols during the third quarter worth about $147,000. Finally, Chesapeake Capital Corp IL purchased a new position in Grifols during the third quarter worth about $148,000.

Grifols Trading Down 2.4 %

Shares of GRFS stock opened at $7.06 on Wednesday. The business’s fifty day moving average price is $8.02 and its 200 day moving average price is $8.18. The firm has a market capitalization of $4.85 billion, a PE ratio of 5.79 and a beta of 0.41. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $9.96.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank raised Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.